266 related articles for article (PubMed ID: 24990656)
1. Drugs associated with adverse events in children and adolescents.
Lee WJ; Lee TA; Pickard AS; Caskey RN; Schumock GT
Pharmacotherapy; 2014 Sep; 34(9):918-26. PubMed ID: 24990656
[TBL] [Abstract][Full Text] [Related]
2. Neurological events with tumour necrosis factor alpha inhibitors reported to the Food and Drug Administration Adverse Event Reporting System.
Deepak P; Stobaugh DJ; Sherid M; Sifuentes H; Ehrenpreis ED
Aliment Pharmacol Ther; 2013 Aug; 38(4):388-96. PubMed ID: 23802849
[TBL] [Abstract][Full Text] [Related]
3. Triptans and serious adverse vascular events: data mining of the FDA Adverse Event Reporting System database.
Roberto G; Piccinni C; D'Alessandro R; Poluzzi E
Cephalalgia; 2014 Jan; 34(1):5-13. PubMed ID: 23921799
[TBL] [Abstract][Full Text] [Related]
4. Pediatric drug surveillance and the Food and Drug Administration's adverse event reporting system: an overview of reports, 2003-2007.
Johann-Liang R; Wyeth J; Chen M; Cope JU
Pharmacoepidemiol Drug Saf; 2009 Jan; 18(1):24-7. PubMed ID: 19009550
[TBL] [Abstract][Full Text] [Related]
5. Surveillance for safety after immunization: Vaccine Adverse Event Reporting System (VAERS)--United States, 1991-2001.
Zhou W; Pool V; Iskander JK; English-Bullard R; Ball R; Wise RP; Haber P; Pless RP; Mootrey G; Ellenberg SS; Braun MM; Chen RT
MMWR Surveill Summ; 2003 Jan; 52(1):1-24. PubMed ID: 12825543
[TBL] [Abstract][Full Text] [Related]
6. Pediatric Drug Safety Surveillance in FDA-AERS: A Description of Adverse Events from GRiP Project.
de Bie S; Ferrajolo C; Straus SM; Verhamme KM; Bonhoeffer J; Wong IC; Sturkenboom MC;
PLoS One; 2015; 10(6):e0130399. PubMed ID: 26090678
[TBL] [Abstract][Full Text] [Related]
7. Antipsychotics, glycemic disorders, and life-threatening diabetic events: a Bayesian data-mining analysis of the FDA adverse event reporting system (1968-2004).
DuMouchel W; Fram D; Yang X; Mahmoud RA; Grogg AL; Engelhart L; Ramaswamy K
Ann Clin Psychiatry; 2008; 20(1):21-31. PubMed ID: 18297583
[TBL] [Abstract][Full Text] [Related]
8. Alleged isotretinoin-associated inflammatory bowel disease: disproportionate reporting by attorneys to the Food and Drug Administration Adverse Event Reporting System.
Stobaugh DJ; Deepak P; Ehrenpreis ED
J Am Acad Dermatol; 2013 Sep; 69(3):393-8. PubMed ID: 23683730
[TBL] [Abstract][Full Text] [Related]
9. Adverse drug event surveillance and drug withdrawals in the United States, 1969-2002: the importance of reporting suspected reactions.
Wysowski DK; Swartz L
Arch Intern Med; 2005 Jun; 165(12):1363-9. PubMed ID: 15983284
[TBL] [Abstract][Full Text] [Related]
10. The Weber effect and the United States Food and Drug Administration's Adverse Event Reporting System (FAERS): analysis of sixty-two drugs approved from 2006 to 2010.
Hoffman KB; Dimbil M; Erdman CB; Tatonetti NP; Overstreet BM
Drug Saf; 2014 Apr; 37(4):283-94. PubMed ID: 24643967
[TBL] [Abstract][Full Text] [Related]
11. Characterization of Pediatric Reports in the US Food and Drug Administration Adverse Event Reporting System from 2010-2020: A Cross-Sectional Study.
Phan M; Cheng C; Dang V; Wu E; Muñoz MA
Ther Innov Regul Sci; 2023 Sep; 57(5):1062-1073. PubMed ID: 37351842
[TBL] [Abstract][Full Text] [Related]
12. Reported Adverse Events with Painkillers: Data Mining of the US Food and Drug Administration Adverse Events Reporting System.
Min J; Osborne V; Kowalski A; Prosperi M
Drug Saf; 2018 Mar; 41(3):313-320. PubMed ID: 29098610
[TBL] [Abstract][Full Text] [Related]
13. Adverse drug and device reactions in the oral cavity: surveillance and reporting.
Zavras AI; Rosenberg GE; Danielson JD; Cartsos VM
J Am Dent Assoc; 2013 Sep; 144(9):1014-21. PubMed ID: 23989840
[TBL] [Abstract][Full Text] [Related]
14. Analysis of anticholinergic adverse effects using two large databases: The US Food and Drug Administration Adverse Event Reporting System database and the Japanese Adverse Drug Event Report database.
Nagai J; Ishikawa Y
PLoS One; 2021; 16(12):e0260980. PubMed ID: 34855908
[TBL] [Abstract][Full Text] [Related]
15. Botulinum toxin type A injections: adverse events reported to the US Food and Drug Administration in therapeutic and cosmetic cases.
Coté TR; Mohan AK; Polder JA; Walton MK; Braun MM
J Am Acad Dermatol; 2005 Sep; 53(3):407-15. PubMed ID: 16112345
[TBL] [Abstract][Full Text] [Related]
16. Atypical antipsychotic drugs and diabetes mellitus in the US Food and Drug Administration Adverse Event database: a systematic Bayesian signal detection analysis.
Baker RA; Pikalov A; Tran QV; Kremenets T; Arani RB; Doraiswamy PM
Psychopharmacol Bull; 2009; 42(1):11-31. PubMed ID: 19204649
[TBL] [Abstract][Full Text] [Related]
17. Effect of Lawyer-Submitted Reports on Signals of Disproportional Reporting in the Food and Drug Administration's Adverse Event Reporting System.
Rogers JR; Sarpatwari A; Desai RJ; Bohn JM; Khan NF; Kesselheim AS; Fischer MA; Gagne JJ; Connolly JG
Drug Saf; 2019 Jan; 42(1):85-93. PubMed ID: 30066315
[TBL] [Abstract][Full Text] [Related]
18. Effects of development on olanzapine-associated adverse events.
Woods SW; Martin A; Spector SG; McGlashan TH
J Am Acad Child Adolesc Psychiatry; 2002 Dec; 41(12):1439-46. PubMed ID: 12447030
[TBL] [Abstract][Full Text] [Related]
19. Adverse event reporting patterns of concomitant botanical dietary supplements with CYP3A4 interactive & CYP3A4 non-interactive anticancer drugs in the U.S. Food and Drug Administration Adverse Event Reporting System (FAERS).
Fahim SM; Mishuk AU; Cheng N; Hansen R; Calderón AI; Qian J
Expert Opin Drug Saf; 2019 Feb; 18(2):145-152. PubMed ID: 30576263
[TBL] [Abstract][Full Text] [Related]
20. Multiple sclerosis as an adverse drug reaction: clues from the FDA Adverse Event Reporting System.
Antonazzo IC; Raschi E; Forcesi E; Riise T; Bjornevik K; Baldin E; De Ponti F; Poluzzi E
Expert Opin Drug Saf; 2018 Sep; 17(9):869-874. PubMed ID: 30058390
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
